Improving the quality of life in patients with chronic obstructive pulmonary disease: Focus on indacaterol

International Journal of COPD

Volumn 8, Issue , 2013, Pages 89-96

  Feldman, Gregory J ^a  

^a S Carolina Pharmaceutical Research   (United States)

Author keywords

Airflow limitation; Bronchodilation; COPD; Long acting 2 agonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; PLACEBO; QVA 149; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; BASELINE DYSPNEA INDEX; BRONCHODILATATION; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DYSPNEA; EXERCISE; EXERCISE TOLERANCE; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HELP SEEKING BEHAVIOR; HYPERINFLATION; LUNG FUNCTION; LUNG VENTILATION; MEDICAL RESEARCH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT CARE; PEAK EXPIRATORY FLOW; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISABILITY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITIONAL DYSPNEA INDEX; TREATMENT OUTCOME;

AIRFLOW LIMITATION; BRONCHODILATION; COPD; LONG-ACTING Β-AGONIST;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DYSPNEA; EXERCISE TOLERANCE; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; SEVERITY OF ILLNESS INDEX;

EID: 84873951882     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S31209     Document Type: Review

References (44)

1. Chronic obstructive pulmonary disease (COPD) fact sheet [webpage on the Internet]. Washington, DC: American Lung Association; 2011. Available from: http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html. Accessed September 14, 2012.
2. National Clinical Guideline Center. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Center; 2010. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed November 14, 2012.
3. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4): 822-832.
4. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomakers. Eur Respir J. 2008;31(2):416-469.
5. Centers for Disease Control and Prevention. Measuring Healthy Days: Population Assessment of Health-Related Quality of Life. Atlanta, GA: Centers for Disease Control and Prevention; 2000. Available from: http://www.cdc.gov/hrqol/pdfs/mhd.pdf. Accessed November 14, 2012.
6. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res. 1993;2(6):451-459.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD; revised 2011. Available from: http://www.Goldcopd.com. Accessed September 14, 2012.
8. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest. 2000;117(Suppl 2):S54-S57.
9. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med. 2006; 119(10 Suppl 1):32-37.
10. Martín A, Rodríguez-González Moro JM, Izquierdo JL, Gobartt E, de Lucas P; VICE Study Group. Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish study. Int J Chron Obstruct Pulmon Dis. 2008;3(4):683-692.
11. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011;20(3):257-268.
12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6): 1321-1327.
13. Feldman G, Siler T, Prasad N, et al; INLIGHT-1study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
14. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2): 273-279.
15. Dahl R, Chung KF, Buhl R, et al; INVOLVE study investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6): 473-479.
16. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2): 155-162.
17. Buhl R, Dunn LJ, Disdier C, et al; INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
18. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011; 105(5):719-726.
19. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.
20. VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives. Indacaterol (Arcapta™ Neohaler™): National Drug Monograph. Washington, DC: US Department of Veterans Affairs; 2012. Available from: http://www.pbm.va.gov/Clinical%20Guidance/drug%20Monographs/Indacaterol.pdf. Accessed November 14, 2012.
21. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol: the FDA's review. N Engl J Med. 2011;365(24):2247-2249.
22. US Food and Drug Administration. Indacaterol FDA Summary Review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000SumR.pdf. Accessed Febuary 2, 2013.
23. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic review. CHEST. 2012;142(5):1104-1110.
24. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99-103.
25. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267-272.
26. Mahler DA, Ward J, Waterman LA, McCusker C, Zuwallack R, Baird JC. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136(6):1473-1479.
27. Jones PW, Barnes N, Vogelmeier C, Lawrence D, Kramer B. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J. 2011;20(4):380-388.
28. Siler TM, Williams J, Yegen U, Owen R, Lassen C, Kramer B. The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-tosevere COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med. 2010;181:A4430.
29. Kleerup E, Williams J, Yegen U, Owen R, Lassen C, Kramer B. The effect of indacaterol once-daily on health-related quality of life, symptoms and rescue medication use in moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of six month. Am J Respir Crit Care Med. 2010;181:A4429.
30. La Piana GE, Corda L, Bertella E, Taranto Montemurro L, Pini L, Tantucci C. Dose-responsive curve to salbutamol during acute and chronic treatment with formoterol in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:399-405.
31. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25-31.
32. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880-887.
33. Jones PW. Interpreting thresholds for a clinically signif icant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398-404.
34. Esteban C, Quintana JM, Aburto M, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J. 2010;36(2):292-300.
35. Palange P, Ward SA, Carlsen KH, et al; ERS Task Force. Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 2007;29(1):185-209.
36. O'Donnell DE, Casaburi R, Vincken W, et al; INABLE 1study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030-1036.
37. Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adv Exp Med Biol. 2013;756:23-28.
38. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79.
39. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(7):554-564.
40. Burge S, Wedzicha JA. COPD exacerbations: def initions and classifications. Eur Respir J Suppl. 2003;41:S46-S53.
41. Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010;36(1):96-104.
42. Mahler DA, Buhl R, Lawrence D, McBryan D. Effectiveness of indacaterol and tiotropium in patients with severe dyspnea. European Respiratory Society Congress; September 1-5, 2012; Vienna, Austria. ERS abstract 850630, session 245.
43. Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Concurrent Use of Indacaterol Plus Tiotropium in Patients with COPD Provides Superior Bronchodilation Compared with Tiotropium Alone. Thorax. 2012;67(9):781-788.
44. Bateman E, Ferguson GT, Barnes N, et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study. European Respiratory Society Congress; September 1-5, 2012; Vienna, Austria. ERS abstract 700179, session 306.